Auravita Therapeutics is pioneering a new class of targeted therapies based on selective modulation of lipid-raft signaling, the control system that governs how cells activate and communicate. Our lead program — a first-in-class oral antibody-drug conjugate (oADC) for inflammatory bowel disease — demonstrates strong preclinical efficacy and validates a platform that can be applied across autoimmune, metabolic, and other lipid-raft-mediated conditions. Our mission is to develop therapies that act locally where disease occurs, delivering high efficacy with fewer systemic side effects.